Effect of selective or combined inhibition of integrins αIIbβ3 and αvβ3 thrombosis and neointima after oversized porcine coronary angioplasty

Circulation

Volumn 103, Issue 8, 2001, Pages 1135-1141

  Chico, Timothy J A ^a,b   Chamberlain, Janet ^a   Gunn, Julian ^a   Arnold, Nadine ^a   Bullens, Sherron L ^b   Gadek, Thomas R ^b   Francis, Sheila E ^a   Bunting, Stuart ^b   Horton, Michael ^c   Shepherd, Lynda ^a   Lipari, Michael T ^b   Quan, Clifford ^b   Knolle, Jochen ^d   Stilz, Hans Ulrich ^d   Peyman, Anusch ^d   Crossman, David C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b GENENTECH INC   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d SANOFI   (France)

Author keywords

Angioplasty; Cell adhesion molecules; Platelets; Thrombosis

Indexed keywords

BETA3 INTEGRIN; INTEGRIN; LAMIFIBAN;

ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL MIGRATION; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG EFFICACY; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SWINE; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

EID: 0035957041     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.8.1135     Document Type: Article

References (28)

1. The vessel wall reaction in restenosis
2. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling
3. Role of platelets in restenosis after percutaneous coronary revascularization
4. Mechanisms of neointima formation: Lessons from experimental models
5. Substantial inhibition of neo-intimal response to balloon injury in the rat carotid artery using a combination of antibodies to platelet-derived growth factor-BB and basic fibroblast growth factor
6. PDGF-β receptor blockade inhibits intimal hyperplasia in the baboon
7. Clues for understanding the structure and function of a prototypic human integrin: The platelet glycoprotein IIb/IIIa complex
8. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
9. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
10. 3 integrins
11. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro
12. Stimulation of migration of human aortic smooth muscle cells by vitronectin: Implications for atherosclerosis
13. Selective alpha v beta 3 integrin blockade potently limits neointimal hyperplasia and lumen stenosis following deep coronary arterial stent injury: Evidence for the functional importance of integrin alpha v beta 3 and osteopontin expression during neointima formation
14. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation
15. Inhibition of neointimal hyperplasia by blocking alpha V beta 3 integrin with a small peptide antagonist GpenGRGDSPCA
16. 1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration
17. 3), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits
18. Low molecular weight, nonpeptide fibrinogen receptor antagonists
19. Design and synthesis of potent and selective peptidomimetic vitronectin receptor antagonists
20. Cyclic RGD peptide analogues as antiplatelet antithrombotics
21. Vascular indications for integrin av antagonists
22. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form
23. 3) mediates platelet adhesion to the luminal aspect of endothelial cells: Implications for reperfusion in acute myocardial infarction
24. Platelet GPIb-V-IX complex
25. 3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells
26. Dissociation between the anti-aggregatory and anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728
27. REVIEW: The integrin alpha V beta 3: Angiogenesis and apoptosis
28. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC. IMPACT II, RESTORE, and EPILOG trials into perspective